Clinical Trial

REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD

Study acronym: REDUCE-PAD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase IIa, multi-centre study conducted at 3 sites in Singapore (SGH and NUHS, KTPH). 70 patients with diabetes mellitus (DM) and peripheral arterial disease (PAD) will be randomised in a ratio 1:1 to receive normal saline control or MEDI6570 400mg by monthly subcutaneous injection for 9 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-11-18
Trial Details
NCT Number NCT05912218
Lead Sponsor National Heart Centre Singapore
Collaborators: Singapore General Hospital, Khoo Teck Puat Hospital, National University Health System, Singapore
Conditions Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Enrollment 70 participants
Start Date 2023-11-02
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-21